The Functions of the Demethylase JMJD3 in Cancer |
| |
Authors: | Anna Sanchez Fatma Zohra Houfaf Khoufaf Mouhamed Idrissou Frdrique Penault-Llorca Yves-Jean Bignon Laurent Guy Dominique Bernard-Gallon |
| |
Affiliation: | 1.Department of Oncogenetics, Centre Jean Perrin, CBRV, 63001 Clermont-Ferrand, France; (A.S.); (F.Z.H.K.); (M.I.); (Y.-J.B.);2.INSERM U 1240 Molecular Imagery and Theranostic Strategies (IMoST), 63005 Clermont-Ferrand, France; (F.P.-L.); (L.G.);3.Department of Biopathology, Centre Jean Perrin, 63011 Clermont-Ferrand, France;4.Department of Urology, Gabriel Montpied Hospital, 63000 Clermont-Ferrand, France |
| |
Abstract: | Cancer is a major cause of death worldwide. Epigenetic changes in response to external (diet, sports activities, etc.) and internal events are increasingly implicated in tumor initiation and progression. In this review, we focused on post-translational changes in histones and, more particularly, the tri methylation of lysine from histone 3 (H3K27me3) mark, a repressive epigenetic mark often under- or overexpressed in a wide range of cancers. Two actors regulate H3K27 methylation: Jumonji Domain-Containing Protein 3 demethylase (JMJD3) and Enhancer of zeste homolog 2 (EZH2) methyltransferase. A number of studies have highlighted the deregulation of these actors, which is why this scientific review will focus on the role of JMJD3 and, consequently, H3K27me3 in cancer development. Data on JMJD3’s involvement in cancer are classified by cancer type: nervous system, prostate, blood, colorectal, breast, lung, liver, ovarian, and gastric cancers. |
| |
Keywords: | JMJD3 cancers H3K27me3 epi-drugs |
|
|